Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data
Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.
You may also be interested in...
Oral proteasome inhibitor fails to reach significance when added to standard combination therapy in first-line myeloma patients who cannot receive marrow transplants, but development continues in other settings.
Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.